TP与NP方案全身化疗治疗NSCLC疗效观察  

Efficacy of TP and NP regimen chemotherapy in the treatment of non-small cell lung cancer

作　　者：李亚星[1] 张晓华[1] 游善喜 刘凌翔[2] 

机构地区：[1]江苏省泰州市第四人民医院肿瘤科,江苏泰州225300 [2]江苏省人民医院肿瘤科,江苏南京210029

出　　处：《实用临床医药杂志》2011年第24期88-90,共3页Journal of Clinical Medicine in Practice

摘　　要：目的研究紫杉醇联合顺铂(TP方案)与长春瑞滨联合顺铂(NP方案)系统化疗治疗中晚期非小细胞肺癌(NSCLC)的疗效观察。方法选择50例NSCLC患者,随机分成2组,每组25例,分别与TP及NP方案治疗,所有患者至少完成2个周期的化疗,评价疗效、生活质量及毒副反应。结果试验组有效率为48%,对照组为44%,试验组略好于对照组。与对照组相比,试验组中位总生存期及中位无进展生存期均无明显统计学差异,不良反应2组亦无明显差异(P>0.05)。结论 TP及NP方案治疗NSCLC,2种化疗方案比较前者略好于后者。Objective To study the effect of Paclitaxel and Cisplatin （rip program） and Vi- norelbine plus Cisplatin （NP program） systemic chemotherapy in the treatment of advanced non- small cell lung cancer （NSCLC）. Methods Fifty cases of NSCLC patients were randomly divided into 2 groups. They were treated with TP and NP program respectively and all patients completed at least two cycles of chemotherapy. Efficacy, quality of life and side effects were evaluated. Results The effective rate was 48 % in the experimental group and 44 % in the control group. The experi- mental group was slightly better than the control group. Compared with the control group, median overall survival and median progression - free survival in the experimental group had no significant difference. No significant difference in adverse reaction was seen between 2 groups （ P 〉 0.05）. Conclusion Compared with NP, TP is slightly better in the treatment of NSCLC.

关 键 词：非小细胞肺癌 紫杉醇 长春瑞滨 顺铂 

分 类 号：R734.2[医药卫生—肿瘤]